BPI Labs has published FAQ pages addressing these questions, though the specific inactive ingredient lists require contacting the company directly for complete details
This section will help you understand the criteria for selecting patients, the contraindications, and special considerations for different populations
While semaglutide and tirzepatide are safe and effective medications, they still require medical oversight
To qualify for weight-management treatment, patients typically need a BMI of 27 or higher, with most programs also considering weight-related health conditions such as high blood pressure, type 2 diabetes, or high cholesterol
This design choice introduces potential bias, particularly for subjective outcomes, but it reflects the practical reality that these treatments have different injection devices and titration schedules that would make blinding extremely difficult
Our team is ready to support your metabolic research programme